Detalhe da pesquisa
1.
Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1.
Blood
; 2024 Apr 24.
Artigo
Inglês
| MEDLINE | ID: mdl-38657201
2.
Teclistamab in Relapsed or Refractory Multiple Myeloma.
N Engl J Med
; 387(6): 495-505, 2022 08 11.
Artigo
Inglês
| MEDLINE | ID: mdl-35661166
3.
Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study.
Cancer
; 130(6): 886-900, 2024 03 15.
Artigo
Inglês
| MEDLINE | ID: mdl-37960969
4.
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.
Blood
; 139(6): 835-844, 2022 02 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34289038
5.
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
Blood
; 139(4): 492-501, 2022 01 27.
Artigo
Inglês
| MEDLINE | ID: mdl-34269818
6.
Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma.
Cancer
; 129(13): 2035-2046, 2023 07 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36991547
7.
Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma.
Future Oncol
; 19(12): 811-818, 2023 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-37132225
8.
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
N Engl J Med
; 380(22): 2104-2115, 2019 05 30.
Artigo
Inglês
| MEDLINE | ID: mdl-31141632
9.
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.
Lancet
; 395(10218): 132-141, 2020 01 11.
Artigo
Inglês
| MEDLINE | ID: mdl-31836199
10.
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL.
Blood
; 134(26): 2361-2368, 2019 12 26.
Artigo
Inglês
| MEDLINE | ID: mdl-31650176
11.
A Multicenter Randomized Three-Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Carcinoma.
Oncologist
; 25(11): 925-e1603, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-32400000
12.
Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma.
Oncologist
; 25(12): e1837-e1845, 2020 12.
Artigo
Inglês
| MEDLINE | ID: mdl-32154962
13.
Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: Efficacy in transplant-ineligible untreated myeloma.
Am J Hematol
; 95(12): 1486-1494, 2020 12.
Artigo
Inglês
| MEDLINE | ID: mdl-32804408
14.
Maintenance chemotherapy to reduce the risk of a metachronous Wilms tumor in children with bilateral nephroblastomatosis.
Pediatr Blood Cancer
; 66(1): e27500, 2019 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30334607
15.
Acute myeloid leukemia therapy elicits durable complete response in chemoradio-resistant metastatic paraganglioma.
Pediatr Blood Cancer
; 64(5)2017 05.
Artigo
Inglês
| MEDLINE | ID: mdl-27804217
16.
Retrospective Evaluation of Palifermin Use in Nonhematopoietic Stem Cell Transplant Pediatric Patients.
J Pediatr Hematol Oncol
; 39(4): e177-e182, 2017 05.
Artigo
Inglês
| MEDLINE | ID: mdl-28234746
17.
Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa.
Biol Blood Marrow Transplant
; 22(8): 1449-1454, 2016 08.
Artigo
Inglês
| MEDLINE | ID: mdl-27184623
18.
Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center.
Pediatr Blood Cancer
; 63(8): 1368-74, 2016 08.
Artigo
Inglês
| MEDLINE | ID: mdl-27082517
19.
Allogeneic hematopoietic stem cell transplantation for nonmalignant hematologic disorders using chemotherapy-only cytoreductive regimens and T-cell-depleted grafts from human leukocyte antigen-matched or -mismatched donors.
Pediatr Hematol Oncol
; 33(6): 347-358, 2016 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-27715384
20.
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.
Lancet Oncol
; 16(3): 284-92, 2015 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-25683846